Shares of Evoke Pharma Inc. (NASDAQ:EVOK) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $2.37 and last traded at $2.47, with a volume of 2,571,393 shares trading hands. The stock had previously closed at $2.89.

EVOK has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Evoke Pharma from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a report on Tuesday, May 3rd. Brean Capital reaffirmed a “buy” rating on shares of Evoke Pharma in a report on Wednesday, April 6th. FBR & Co reaffirmed a “buy” rating on shares of Evoke Pharma in a report on Saturday, May 14th. Finally, Rodman & Renshaw reaffirmed a “buy” rating on shares of Evoke Pharma in a report on Thursday, May 12th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $13.34.

The company has a 50-day moving average of $6.59 and a 200-day moving average of $4.81. The stock’s market capitalization is $17.88 million.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.04. Equities research analysts expect that Evoke Pharma Inc. will post ($1.41) EPS for the current fiscal year.

In other Evoke Pharma news, major shareholder Parters Vii L. P. Domain sold 41,478 shares of the stock in a transaction that occurred on Wednesday, April 20th. The stock was sold at an average price of $5.35, for a total transaction of $221,907.30. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Parters Vii L. P. Domain sold 344,120 shares of the stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $4.70, for a total value of $1,617,364.00. The disclosure for this sale can be found here.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.